[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597737":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgery-Only Validation Cohort",null,"Patients with early-stage HCC (BCLC 0-A) receiving curative liver resection without neoadjuvant\u002Fadjuvant therapy . Preoperative MRI, clinical data and pathological data will be used for AI model prediction of recurrence risk. Standard follow-up imaging for 2 years will validate model accuracy.",[13],"Procedure: Curative liver resection",{"label":15,"type":10,"description":16,"interventionNames":17},"Exploratory Treatment Cohort","Patients with early-stage HCC receiving real-world neoadjuvant\u002Fadjuvant therapies (per physician discretion) alongside surgery. Treatment regimens and outcomes (RFS\u002FOS) will be analyzed to assess therapy efficacy in model-stratified high\u002Flow-risk subgroups.",[18],"Procedure: Real-world multimodal therapy",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"PROCEDURE","Curative liver resection","Standard radical hepatectomy performed according to 2024 HCC guidelines. No neoadjuvant or adjuvant therapies administered. Follows institutional surgical protocols for BCLC 0-A HCC.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Real-world multimodal therapy","Curative resection combined with clinically indicated therapies (e.g., TACE, targeted drugs, immunotherapy) as per treating physician's decision. Treatments recorded but not protocol-mandated.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Yang Wu, M.D.","CONTACT","+8613636076910","255001907@qq.com",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Wuhan","Hubei","430030","China","CN",{"type":44,"coordinates":45},"Point",[46,47],114.26667,30.58333,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":10,"email":53},"Wanguang Zhang","13636076910","wgzhang@tjh.tjmu.edu.cn",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Wan-Guang Zhang","professor","100597737","ai-based-prediction-of-hcc-recurrence-patterns-after-resection-apar-100597737",false,"NCT07062380","AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)","Prospective Validation of Multimodal Deep Learning Models for Predicting Recurrence Patterns in Early-Stage Hepatocellular Carcinoma After Resection: A Natural Treatment Cohort Stratification Study","Inclusion Criteria:\n\n* Aged 18-75 years, regardless of gender.\n* BCLC stage 0-A, scheduled for curative liver resection.\n* Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).\n* Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.\n* Child-Pugh liver function score ≤7.\n* ECOG Performance Status (PS) 0-1.\n* No severe organic diseases of the heart, lungs, brain, or other vital organs.\n\nExclusion Criteria:\n\n* Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).\n* Postoperative pathology confirms non-HCC diagnosis.\n* Pregnant or lactating women.\n* History of organ transplantation.\n* Inability to comply with the study protocol or follow-up schedule.","ALL","18 Years","75 Years",{"count":69,"type":70},353,"ESTIMATED","OBSERVATIONAL","This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.\n\nThe main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.",[74,75],"Hepatecellular Carcinoma","Hepatectomy","2025-08-26",{"date":78,"type":79},"2025-09-03","ACTUAL",{"date":81,"type":79},"2025-06-10",{"date":83,"type":70},"2028-06-10",{"name":5,"class":6},1]